- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01485809
Efficacy and Safety Study of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy (SIIS)
A Phase II Trial of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy
Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC). Results from two randomised phase II trials (IDEAL 1 and 2) suggested that gefitinib was efficacious and less toxic, compared with previous results, than was chemotherapy in patients with previously-treated non-small-cell lung cancer. Two phase III trials of gefitinib in advanced non-small-cell lung cancer followed on from the IDEAL phase II studies: Iressa Survival Evaluation in Lung cancer (ISEL) and Iressa NSCLC Trial Evaluating REsponse and Survival versus Taxotere (INTEREST). Although the phase III ISEL trial failed to prove the superiority of gefitinib treatment compared to placebo in previously treated patients, a subgroup analysis demonstrated improved survival in particular populations (Asians and non-smokers). The INTEREST study compared an EGFR tyrosine kinase inhibitor with chemotherapy in pretreated advanced non-small-cell lung cancer. In INTEREST, survival was similar for gefitinib and docetaxel in almost all subgroups; no EGFR-related biomarker or any clinical factor (including female sex, adenocarcinoma histology, never-smoker, and Asian ethnicity) appeared to be predictive of a greater survival benefit for gefitinib versus docetaxel. However, these factors may still be predictive of a greater survival benefit for gefitinib and/or docetaxel versus best supportive care; alternatively, they may just be good prognostic factors. Progression free survival and overall response rate was no statistically significant difference between gefitinib and docetaxel. This suggests gefitinib can provide similar overall survival to docetaxel in pretreated advanced non-small-cell lung cancer patients. These studies have demonstrated that gefitinib is effective for the second-line treatment of NSCLC. Now, gefitinib is recommended in advanced and metastatic NSCLC as second-line chemotherapy.
But, there was no prospective study with gefitinib in NSCLC wih squamous cell histology. This trial will investigate the efficacy and safety of gefitinib in locally advanced, metastatic NSCLC patients with squamous cell histology who have failed first-line chemotherapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Taekyu Lim, M.D
- Phone Number: +82-2-2225-1599
- Email: sksek79@naver.com
Study Locations
-
-
-
Seoul, Korea, Republic of, 134-791
- Recruiting
- Seoul Veterans Hospital
-
Contact:
- Taekyu Lim, M.D
- Phone Number: +82-2-2225-1599
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed locally advanced(stage IIIB or IV) squamous NSCLC
- Failure of only one first line chemotherapy for advanced disease
- At least one lesion that unidimensionally measurable by computed tomography (RECIST 1.1)
- Performance status: ECOG 0-2
- Age ≥20
- Adequate renal function: serum creatinine level < 2 mg/dL (177 μmol/L)
Adequate liver functions
- : Transaminase (AST/ALT) < 2 X upper normal value
- Bilirubin < 2 X upper normal value
- Adequate hematological function: hemoglobin ≥ 9 g/dL absolute neutrophil count (ANC) ≥ 1,500/μL and platelet count ≥ 100,000/μL
- Life expectancy 3 months
- Written Informed consent prior to any study specific procedures
- NSCLC with an activating sensitizing EGFR mutation
Exclusion Criteria:
- Two or more chemotherapy treatment regimen for advanced disease
- Previous therapy with other EGFR-TKI related drug
- Known or suspected brain metastases or spinal cord compression
- Radiotherapy within 4 weeks before study entry
- Any other malignancies within the past 5 years except curatively treated non-melanoma skin cancer or in situ carcinoma of cervix uteri
- Pregnant or lactating women
- Other serious illness or medical conditions as judged by the investigator
- Known severe hypersensitivity to gefitinib or any of the excipients of the product
- Concomitant administration of any other experimental drug under investigation, or concomitant chemotherapy, hormonal therapy, or immunotherapy.
- Presence of EGFR mutation reported to confer resistance to EGFR TKI: exon 20 point mutation (T790M or S768I EGFR) or exon 20 insertion
- Any unresolved chronic toxicity greater than CTC grade 2 from previous anticancer therapy.
- Concomitant use of known CYP 3A4 inducers such as phenytoin, carbamazepine, rifampicin, barbiturates,
- Involvement in the planning and/or conduct of the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Gefitinib
|
Gefitinib 250mg/day, oral daily q every 4 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease control rate (complete response, partial response, or stable disease) at 8 weeks
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
number of participants with adverse events as a measure of safety and tolerability
Time Frame: 2 years
|
safety & tolerability: NCI CTCAE version 4.0
|
2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bong-Seog Kim, M.D, Seoul Veterans Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SVH-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Squamous Cell Carcinoma of Bronchus
-
Kyunghee Burkitt, DO, PhDNot yet recruitingSquamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | HPV-Related Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the HypopharynxUnited States
-
AIO-Studien-gGmbHMerck Sharp & Dohme LLCNot yet recruitingSquamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the HypopharynxGermany
-
University of Erlangen-Nürnberg Medical SchoolRecruitingSquamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the HypopharynxGermany
-
Terrence JonesNestléCompletedLaryngeal Squamous Cell Carcinoma | Squamous Cell Carcinoma of Oropharynx | Squamous Cell Carcinoma of Mouth | Squamous Cell Carcinoma of the HypopharynxUnited Kingdom
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma of the Hypopharynx | Metastatic Squamous Cell Carcinoma of the Larynx | Metastatic Squamous Cell Carcinoma of the Oral Cavity | Metastatic Squamous Cell Carcinoma of the Oropharynx | Recurrent Hypopharyngeal... and other conditionsUnited States
-
Charite University, Berlin, GermanyCompletedSquamous Cell Carcinoma of the Neck | Squamous Cell Carcinoma of the HeadGermany
-
H. Lee Moffitt Cancer Center and Research InstituteBristol-Myers Squibb; Eli Lilly and Company; James and Esther King Biomedical...Active, not recruitingHead and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma | Squamous Cell Carcinoma of the Larynx | Squamous Cell Carcinoma of the Oral Cavity | Squamous Cell Cancer | Squamous Cell Carcinoma of the Oropharynx | Squamous Cell Carcinoma of the Hypopharynx | Squamous Cell Carcinoma of the Paranasal...United States
-
Arbeitsgemeinschaft medikamentoese TumortherapieMedical University of GrazTerminatedLocally Advanced Malignant Neoplasm | Squamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Oral Cavity Stage III | Squamous Cell Carcinoma of the Oral Cavity Stage IV | Laryngeal Squamous Cell Carcinoma Stage... and other conditionsAustria
-
Arbeitsgemeinschaft medikamentoese TumortherapieCompletedSquamous Cell Carcinoma of the Hypopharynx Stage III | Squamous Cell Carcinoma of the Hypopharynx Stage IV | Squamous Cell Carcinoma of the Larynx Stage III | Squamous Cell Carcinoma of the Larynx Stage IV | Squamous Cell Carcinoma of the Oropharynx Stage III | Squamous Cell Carcinoma of the... and other conditionsAustria
-
University Health Network, TorontoAstraZeneca; Mirati Therapeutics Inc.WithdrawnSquamous Cell Carcinoma, Head And Neck | Squamous Cell Carcinoma Mouth | Resectable Squamous Cell Carcinoma of Oral CavityCanada
Clinical Trials on Gefitinib
-
Sun Yat-sen UniversityUnknown
-
Qilu Pharmaceutical Co., Ltd.UnknownNon-small-cell Lung CancerChina
-
Sun Yat-sen UniversityWu Jieping Medical FoundationCompletedNon-small Cell Lung CancerChina
-
Jiangsu Famous Medical Technology Co., Ltd.UnknownNon-small Cell Lung Cancer
-
AstraZenecaCompletedNeoplasms, Squamous CellUnited States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
-
Anhui Medical UniversityUnknownSelf Efficacy | Drug ToxicityChina
-
NCIC Clinical Trials GroupCompletedProstate CancerCanada
-
University of Maryland, BaltimoreNational Cancer Institute (NCI); University of Maryland Greenebaum Cancer CenterCompleted
-
Samsung Medical CenterUnknownNon-small Cell Lung CancerKorea, Republic of
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Cancer | Primary Peritoneal Cavity CancerUnited States, Canada, United Kingdom, Australia